The study, titled “ Strategic Help with Immunoglobulin to Enhance protection against Late Disease (CMV) ” or SHIELD, is a prospective, randomized, controlled multicenter investigator-initiated study ...
Kamada begins patient enrolment in an investigator-initiated clinical trial of Cytogam to prevent cytomegalovirus in kidney transplantation: Rehovot, Israel Thursday, November 6, ...
Live Science on MSN
Aging and inflammation may not go hand in hand, study suggests
Declining immune responsiveness with age may be driven by changes in immune cells — not by inflammation, as previously ...
Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated immunotherapies for the treatment of cancer and autoimmune diseases, today ...
GlobalData on MSN
Kamada enrols first subject in Cytogam trial for CMV infection
The controlled multi-centre, randomised, prospective trial is investigating the therapy in kidney transplant recipients.
A comprehensive eight-year study examining audiological outcomes of newborns screened for congenital cytomegalovirus (cCMV) ...
Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once touted as a future blockbuster – after it failed the Phase 3 CMVictory trial ...
First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session ...
Over the past 10 years, the market for monoclonal antibodies has grown exponentially. This focus issue brings together articles on the basic biology of antibodies and their therapeutic use, providing ...
Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase 3 programme after a phase 2b data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback